ZA200509379B - Memantine oral dosage forms - Google Patents

Memantine oral dosage forms

Info

Publication number
ZA200509379B
ZA200509379B ZA200509379A ZA200509379A ZA200509379B ZA 200509379 B ZA200509379 B ZA 200509379B ZA 200509379 A ZA200509379 A ZA 200509379A ZA 200509379 A ZA200509379 A ZA 200509379A ZA 200509379 B ZA200509379 B ZA 200509379B
Authority
ZA
South Africa
Prior art keywords
dosage forms
oral dosage
memantine oral
memantine
forms
Prior art date
Application number
ZA200509379A
Other languages
English (en)
Inventor
Bruce A Firestone
Janet K Cheetham
Teresa H Kuan
J Abraham M Espiritu
Zanden John J Vander
Kurjan Richard
Chang Chin-Ming
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of ZA200509379B publication Critical patent/ZA200509379B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200509379A 2003-06-16 2005-11-17 Memantine oral dosage forms ZA200509379B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47897903P 2003-06-16 2003-06-16

Publications (1)

Publication Number Publication Date
ZA200509379B true ZA200509379B (en) 2006-11-29

Family

ID=33539133

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200509379A ZA200509379B (en) 2003-06-16 2005-11-17 Memantine oral dosage forms

Country Status (16)

Country Link
US (2) US20040254251A1 (fr)
EP (1) EP1631273A1 (fr)
JP (1) JP2006527774A (fr)
KR (1) KR20060033727A (fr)
CN (1) CN1805737A (fr)
AU (1) AU2004249151A1 (fr)
BR (1) BRPI0411451A (fr)
CA (1) CA2529535A1 (fr)
IL (1) IL172233A0 (fr)
MX (1) MXPA05012810A (fr)
NO (1) NO20055880L (fr)
PL (1) PL378902A1 (fr)
RU (1) RU2006101225A (fr)
TW (1) TW200524639A (fr)
WO (1) WO2004112768A1 (fr)
ZA (1) ZA200509379B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
FR2855344A1 (fr) * 2003-05-22 2004-11-26 France Telecom Systeme de gestion de contexte pour un reseau comportant un ensemble heterogene de terminaux
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
EP2601937A1 (fr) * 2004-06-17 2013-06-12 Merz Pharma GmbH & Co. KGaA Comprimes buvables a liberation immediate, faits par compression directe, de memantine ou de neramexane
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006058059A2 (fr) * 2004-11-23 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Procede et composition pour administrer un antagoniste du recepteur de nmda a un sujet
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
AU2005320547B2 (en) 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
EP2243475B1 (fr) 2005-04-06 2016-01-13 Adamas Pharmaceuticals, Inc. Combinaison de mémantine et donépézil pour le traitement de conditions relatives au SNC
US20090023778A1 (en) * 2005-04-28 2009-01-22 Eisai R&D Management Co., Ltd. Composition Containing Anti-Dementia Drug
PL1994012T3 (pl) * 2006-02-10 2010-05-31 Janssen Pharmaceutica Nv Nowe tricykliczne dihydropirazyny jako środki otwierające kanały potasowe
CA2649272A1 (fr) * 2006-04-20 2007-11-01 Itoham Foods Inc. Composition pharmaceutique pour maladie conformationnelle
CA2654523A1 (fr) * 2006-07-05 2008-01-10 Teva Pharmaceutical Industries Ltd. Composition pharmaceutique de memantine
EP1908748A1 (fr) * 2006-10-05 2008-04-09 Krka Procédé de préparation de memantine et du chlorohydrate de memantine
WO2008051599A2 (fr) * 2006-10-27 2008-05-02 Medivation Neurology, Inc. Procédés et combinaison de thérapies pour le traitement de la maladie d'alzheimer
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
EP2170310A4 (fr) * 2007-06-29 2010-06-23 Orchid Chemicals & Pharm Ltd Compositions à dissolution rapide de chlorhydrate de mémantine
WO2009084017A2 (fr) 2007-10-10 2009-07-09 Rubicon Research Private Limited Comprimés de chlorhydrate de mémantine à dissolution orale et au goût masqué
WO2009091932A2 (fr) * 2008-01-18 2009-07-23 Adamas Pharmaceuticals, Inc. Traitement de la démence légère du type de la maladie d'alzheimer
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
CA2994873A1 (fr) 2009-12-02 2011-06-09 Adamas Pharmaceuticals, Inc. Compositions d'amantadine et procedes d'utilisation associes
ES2694224T3 (es) 2012-04-24 2018-12-19 Daiichi Sankyo Company, Limited Comprimido de desintegración oral y procedimiento para producir el mismo
WO2014204933A1 (fr) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Compositions d'amantadine et procédés d'utilisation
KR20190076711A (ko) 2017-12-22 2019-07-02 한미약품 주식회사 메만틴을 포함하는 속방성 및 서방성을 동시에 가지는 경질캡슐 제제 및 그 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US6849271B2 (en) * 2001-04-27 2005-02-01 Verion, Inc. Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods

Also Published As

Publication number Publication date
PL378902A1 (pl) 2006-05-29
CA2529535A1 (fr) 2004-12-29
US20040254251A1 (en) 2004-12-16
EP1631273A1 (fr) 2006-03-08
JP2006527774A (ja) 2006-12-07
IL172233A0 (en) 2006-04-10
MXPA05012810A (es) 2006-02-13
RU2006101225A (ru) 2006-06-10
CN1805737A (zh) 2006-07-19
NO20055880L (no) 2005-12-28
US20060251717A1 (en) 2006-11-09
TW200524639A (en) 2005-08-01
AU2004249151A1 (en) 2004-12-29
WO2004112768A1 (fr) 2004-12-29
BRPI0411451A (pt) 2006-07-18
KR20060033727A (ko) 2006-04-19

Similar Documents

Publication Publication Date Title
IL172233A0 (en) Memantine oral dosage forms
GB0322284D0 (en) Medicament dispenser
AU2003244650A8 (en) Medicinal compounds
GB0204719D0 (en) Medicinal compounds
HK1107768A1 (en) Solid drug for oral use
IL174342A0 (en) Chronotherapeutic dosage forms
GB0324886D0 (en) Medicinal compounds
IL172824A0 (en) Pharmaceutical formulations
EP1553925A4 (fr) Forme posologique orale a liberation modifiee
GB0302671D0 (en) Pharmaceutical formulations
GB0303396D0 (en) Medicinal compounds
AU2003238670A8 (en) Fast disintegrating oral dosage forms
GB0209668D0 (en) Oral devices
GB0302672D0 (en) Pharmaceutical formulations
GB0328490D0 (en) Medicinal compounds
HK1092715A1 (en) Melt-formulated, multi-particulate oral dosage form
GB0325383D0 (en) Oral formulations
GB0206505D0 (en) Pharmaceutical combination
GB0316341D0 (en) Pharmaceutical formulations
EP1614417A4 (fr) Preparation solide pour l'usage par voie orale
PL373409A1 (en) Pharmaceutical combination
ZA200600560B (en) Combined doses
GB0315019D0 (en) Dosage form
GB0316335D0 (en) Pharmaceutical formulations
GB0220451D0 (en) Pharmaceutical use